Rizzoli Orthopaedic Institute, Pharmacogenomics and Pharmacogenetics Research Unit, Laboratory of Experimental Oncology, Via di Barbiano 1/10, 40136 Bologna, Italy.
Expert Opin Emerg Drugs. 2010 Dec;15(4):615-34. doi: 10.1517/14728214.2010.505603. Epub 2010 Aug 9.
Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. This review focuses on the most promising therapeutic markers and drugs which may potentially be considered for innovative high-grade OS treatments.
The list of drugs and compounds reviewed has been generated by taking into account those which target markers of potential clinical interest for high-grade OS and have been included in Phase I, II or III clinical trials. The literature search covers the last 40 years, starting from the first OS chemotherapy reports of the early 1970s. Particular relevance was given to reports and reviews on new targeted therapies of possible clinical usefulness for high-grade OS.
This review gives an updated overview of novel therapeutic approaches which have been or are going to be evaluated in Phase I/II/III clinical studies for high-grade OS.
On the basis of the information that has emerged so far, it can be predicted that in the next 5 - 10 years, new agents to be included in innovative treatment strategies for selected subgroups of high-grade OS patients may become available.
骨肉瘤（OS）是最常见的原发性恶性骨肿瘤在儿童和青少年。这篇综述主要关注最有前途的治疗标志物和药物，可能会被认为是创新的高级 OS 治疗。
审查中所涉及的药物和化合物的列表是通过考虑那些针对高级 OS 的潜在临床感兴趣的标志物，并已被列入 I 期，II 期或 III 期临床试验。文献检索涵盖了过去 40 年，从 20 世纪 70 年代初首次 OS 化疗报告开始。特别关注的是关于新的靶向治疗的报告和评论，这些治疗对高级 OS 的可能具有临床意义。
这篇综述提供了一个更新的高级 OS 的 I/II/III 期临床研究中已经或即将进行的新的治疗方法概述。
根据迄今为止出现的信息，可以预测，在未来 5-10 年内，新的药物将被纳入高级 OS 选定亚组的创新治疗策略中。
